Bristol Myers Squibb's Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb (NYSE:BMY) announced six-year results from Part 1 of the Phase 3 CheckMate -227 trial, demonstrating long-term survival benefits of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to chemotherapy in the first-line treatment of patients with metastatic non-small cell lung cancer. The results will be presented at the IASLC 2023 World Conference on Lung Cancer.
September 11, 2023 | 11:00 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb's successful trial results for Opdivo and Yervoy in treating metastatic non-small cell lung cancer could potentially boost the company's market position and stock value.
Positive trial results often lead to increased investor confidence, potentially driving up the stock price. The successful trial results could also lead to increased sales of Opdivo and Yervoy, boosting the company's revenues.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100